Anemia News and Research

RSS
Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.
UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

Combination therapy provides promising results in patients with advanced non-small cell lung cancer

Combination therapy provides promising results in patients with advanced non-small cell lung cancer

EKF highlighting its expanding range of liquid stable clinical chemistry reagents at Hospitalar 2015

EKF highlighting its expanding range of liquid stable clinical chemistry reagents at Hospitalar 2015

Investigational three-drug combination clears hepatitis C in 93% of patients with liver cirrhosis

Investigational three-drug combination clears hepatitis C in 93% of patients with liver cirrhosis

ITIM-containing receptor crucial for development of acute myeloid leukemia

ITIM-containing receptor crucial for development of acute myeloid leukemia

Rudolf Jaenisch honored with 2015 March of Dimes Prize in Developmental Biology

Rudolf Jaenisch honored with 2015 March of Dimes Prize in Developmental Biology

Molecular Health granted European patent for novel Erythropoietin receptor

Molecular Health granted European patent for novel Erythropoietin receptor

Combination therapy effective in HCV patients with advanced cirrhosis and post-transplant recurrence

Combination therapy effective in HCV patients with advanced cirrhosis and post-transplant recurrence

New data supports use DAAs in patients with HCV recurrence following liver transplantation

New data supports use DAAs in patients with HCV recurrence following liver transplantation

AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Alternative treatment options for uterine fibroids

Alternative treatment options for uterine fibroids

Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO

Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO

Experimental immune therapy generally safe, well-tolerated in women with triple-negative breast cancer

Experimental immune therapy generally safe, well-tolerated in women with triple-negative breast cancer

MGH researchers find probable mechanism associated with risk of developing serious diseases

MGH researchers find probable mechanism associated with risk of developing serious diseases

Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Latest findings regarding nitric oxide offer new avenues to save lives

Latest findings regarding nitric oxide offer new avenues to save lives

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Pharmacyclics announces positive results from IMBRUVICA Phase II study in WM patients

Pharmacyclics announces positive results from IMBRUVICA Phase II study in WM patients

Clinical trial uses personalized cellular therapy to treat GVHD complication of bone marrow transplant

Clinical trial uses personalized cellular therapy to treat GVHD complication of bone marrow transplant

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.